Get the Stockscreener App
7.36
0.68%
0.05
After Hours:
7.23
-0.13
-1.77%
Transcode Therapeutics Inc stock is traded at $7.36, with a volume of 2.26M.
It is up +0.68% in the last 24 hours and down -14.52% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$7.31
Open:
$7.21
24h Volume:
2.26M
Relative Volume:
13.11
Market Cap:
$6.75M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0277
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
+14.29%
1M Performance:
-14.52%
6M Performance:
-12.90%
1Y Performance:
-92.47%
1-Day Range:
$6.50
$8.20
1-Week Range:
$6.50
$8.20
52-Week Range:
$6.0829
$468.44
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
7.36 | 6.70M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
TransCode Therapeutics Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma Treatment - citybuzz -
Transcode Therapeutics Ttx-Mc138 phase 2a clinical trial expected in first half of 2026 - marketscreener.com
Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026 - TradingView — Track All Markets
TransCode Therapeutics reports promising preclinical glioblastoma results - TipRanks
TransCode Therapeutics stock soars after promising glioblastoma study By Investing.com - Investing.com Canada
TransCode’s glioblastoma therapy shows promise in preclinical study By Investing.com - Investing.com Canada
TransCode Therapeutics Publishes Preclinical Data on TTX-MC138 for Glioblastoma - TradingView — Track All Markets
Experimental RNA therapy extends survival in brain cancer animal tests - Stock Titan
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics appoints Jack E. Stover to board of directors By Investing.com - Investing.com Nigeria
TransCode Therapeutics Appoints Industry Veteran Jack E. Stover to Board of Directors - citybuzz -
TransCode Therapeutics Strengthens Board with Veteran Financial Expert - TipRanks
Transcode Therapeutics Appoints Jack Stover to Board of Directors - TradingView — Track All Markets
TransCode Therapeutics appoints Jack E. Stover to board of directors - Investing.com India
TransCode Therapeutics expands leadership with appointment of Jack E. Stover to board of directors - marketscreener.com
Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors - TradingView — Track All Markets
Life sciences leader behind a $900M pharma sale joins cancer firm - Stock Titan
Why TransCode Therapeutics Inc. stock is favored by top institutionsQuarterly Market Summary & Real-Time Buy Zone Alerts - Улправда
TransCode Therapeutics Earnings Notes - Trefis
Is TransCode Therapeutics Inc. stock in correction or buying zoneJuly 2025 Sector Moves & Free Risk Controlled Daily Trade Plans - DonanımHaber
How TransCode Therapeutics Inc. stock benefits from tech adoptionMarket Volume Summary & Daily Profit Maximizing Trade Tips - Улправда
TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 4.6% – Here’s What Happened - Defense World
MSN Money - MSN
TransCode Therapeutics Inc Stock Analysis and ForecastMACD Histogram Signals & Superior Trading Ideas - earlytimes.in
TransCode and Quantum Leap to test cancer therapy in phase 2a trial - Investing.com Australia
TransCode Therapeutics and Quantum Leap Collaborate on Colorectal Cancer Trial Targeting Metastatic Disease - citybuzz
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode and Quantum Leap to test cancer therapy in phase 2a trial By Investing.com - Investing.com South Africa
TransCode Therapeutics and Quantum Leap Healthcare Collaborative launch a phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's phase 1 trial - marketscreener.com
TransCode Therapeutics Announces Phase 2a Trial Collaboration - TradingView — Track All Markets
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PR Newswire
Buyout Rumor: Why hedge funds are buying NETSTREIT Corp. stockInsider Selling & Expert Curated Trade Ideas - moha.gov.vn
Critical Comparison: TransCode Therapeutics (NASDAQ:RNAZ) & ReNeuron Group (OTCMKTS:RNUGF) - Defense World
Will TransCode Therapeutics Inc. stock see PE expansion2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
Is TransCode Therapeutics Inc. stock supported by strong cash flows2025 Top Gainers & AI Enhanced Execution Alerts - Newser
Alzamend Neuro (ALZN) Stock Analysis Report | Financials & Insights - Benzinga
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - MSN
Is TransCode Therapeutics Inc. stock a contrarian buyRecession Risk & Technical Pattern Recognition Alerts - newser.com
TransCode Therapeutics, Inc. (RNAZ) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Real time breakdown of TransCode Therapeutics Inc. stock performanceEarnings Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
What technical models suggest about TransCode Therapeutics Inc.’s comeback2025 Dividend Review & Accurate Buy Signal Alerts - newser.com
Can TransCode Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Is TransCode Therapeutics Inc. stock resilient to inflationMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
TransCode Therapeutics Inc. recovery potential after sell offQuarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
Will TransCode Therapeutics Inc. stock outperform value stocks2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Avidity Biosciences Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why retail investors favor TransCode Therapeutics Inc. stockWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):